Home › Sexually Transmitted Infections › NCT07088419

"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"

Tinidazole for Mycoplasma Genitalium-Urethritis in the Public Health - Seattle & King County Sexual Health Clinic

Who can join

Ages 18 and older · Men

Inclusion Criteria:

* ≥18 years of age
* Clinical diagnosis of NGU
* Urogenital MG documented by a positive NAAT in the prior 7 days
* Fluent in English
* Assigned male at birth
* Attending the PHSKC SHC
* Able to provide informed consent
* Able to undergo a test of cure (TOC) 21 days after completing the tinidazole regimen

Exclusion Criteria:

* Known allergy to tinidazole
* Other contraindications to tinidazole
* At the clinician's discretion

About the study

The objective is to estimate the efficacy of tinidazole for the treatment of Mycoplasma genitalium (MG) among male patients who have been diagnosed with non-gonococcal urethritis (NGU) at the Public Health - Seattle \&King County (PHSKC) Sexual Health Clinic (SHC). Tinidazole was approved by the Food and Drug Administration (FDA) in May 2004 to treat other infections (i.e., trichomoniasis, giardiasis, amebiasis, bacterial vaginosis) but has not been systematically tested for effectiveness against M. genitalium. The dosing that the investigators are proposing does not significantly increase the risk associated with taking tinidazole and this investigation meets criteria for an IND exemption.

What is being tested

• Tinidazole (drug)

Sponsor: University of Washington · Participants: 40 · Started: Jul 23, 2025

Contact the study team

• Lisa Manhart, PhD, MPH · Phone: 206 744-3646

Official record on ClinicalTrials.gov — NCT07088419

Locations in the U.S.

Conditions

• Sexually Transmitted Infections

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.